Tamm-Horsfall Glycoprotein Immunostimulating Drug for Tumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective solutions for inhibiting tumor development and enhancing immune innate response, particularly in immunocompromised individuals and those with tumors.
Innovation Solution
A pharmaceutical composition comprising native or pegylated Tamm-Horsfall glycoprotein (THP) is administered parenterally to mammals, leveraging its immunostimulating properties to inhibit tumor growth and increase immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tumor therapies are used, then tumor development can be inhibited to some extent, but the immune innate response is not effectively enhanced
Solution Approach 1:
The patent employs Tamm-Horsfall glycoprotein (THP) as a multi-functional therapeutic agent that simultaneously inhibits tumor development and enhances immune innate response. THP acts as both a direct antitumor agent and an immunostimulant, improving phagocytosis and activating immune cells, thereby resolving the contradiction between tumor inhibition and immune response enhancement.
Solution Approach 2:
THP serves as an intermediary substance that bridges the gap between tumor suppression and immune activation. The glycoprotein mediates these effects by interacting with both tumor cells and immune cells, facilitating coordinated action between direct tumor killing and immune system activation.
2Adaptability or versatility
If immunostimulating agents are administered to enhance immune response, then immune innate response increases, but tumor development inhibition is not achieved
Solution Approach 1:
THP is positioned as a universal therapeutic agent that performs multiple functions: it stimulates immune response through phagocytosis enhancement and immune cell activation, while simultaneously exerting direct antitumor effects. This dual functionality resolves the contradiction between immune enhancement and tumor inhibition.
3Reliability
If therapeutic agents are used to inhibit tumor development, then tumor growth is reduced, but the complexity of treatment protocols increases
Solution Approach 1:
THP exhibits self-regulating properties where the glycoprotein naturally activates immune responses and inhibits tumor growth through its inherent biological activities. The agent utilizes the body's own immune system mechanisms, reducing the need for complex multi-drug protocols or sophisticated delivery systems.
Data Source
AI summary
The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.